← Eichor
Study identifier: NCT05058781 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Minipuberty in Infants Born With Potential Hypogonadism Hypogonadotrope

Condition: DSD · CHH  ·  Sponsor: Centre Hospitalier Universitaire Vaudois

PhaseN/A
Planned participants100
Who can joinAll sexes, N/A to 9 Months
Healthy volunteersYes

About this study

Disorders of sex development (DSD) occur in 1/3000 births and are defined by variation in aspect of external genital organs, e.g. cryptorchidism, hypospadias and micropenis in male infants and clitoral hypertrophy in female infants. Genetic, hormonal and environmental factors are implicated in DSD. Infants with congenital hypogonadism hypogonadotrope (CHH) can present with DSD. Evaluation of hormonal profile during minipuberty could be of great help to better characterize the etiology of DSD and CHH in particular. Our main objective is to study hormonal profile during the minipuberty of infants born with DSD or born from parents with CHH compared to controls.

This description comes directly from the study's public registry record.

Talk to the study team

Nelly Pitteloud, MD  ·  +41 79 556 27 36  ·  nelly.pitteloud@chuv.ch

Research assistant  ·  +41 (0)79 556 37 50  ·  edm.biobank@chuv.ch

Always discuss trial participation with your own doctor first.

Locations (1)

Centre Hospitalier Universitaire Vaudois (CHUV)Lausanne, Canton of Vaud, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05058781